Framingham Risk Score Explained: 10-Year Heart Disease Risk & Prevention
Quick Answer
- *The Framingham Risk Score predicts a person's 10-year probability of a major coronary event (heart attack or coronary death) using eight clinical inputs.
- *Key inputs include age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, BP treatment, smoking, and diabetes.
- *Risk categories: low = less than 10%, intermediate = 10–19%, high = 20% or more.
- *ACC/AHA guidelines recommend statin discussions when 10-year ASCVD risk reaches 7.5% or higher.
What Is the Framingham Risk Score?
The Framingham Risk Score (FRS) is a sex-specific algorithm that estimates the 10-year probability of developing coronary heart disease (CHD) in patients without pre-existing cardiovascular disease. It was derived from the landmark Framingham Heart Study, which the National Heart, Lung, and Blood Institute (NHLBI) launched in 1948in Framingham, Massachusetts — one of the longest-running cardiovascular cohort studies in history.
The modern point-based version, introduced by Wilson et al. in 1998 and updated by D'Agostino et al. in 2008, scores patients across eight clinical variables and maps the total to a predicted 10-year risk percentage. Physicians use the result to guide conversations about statins, aspirin, lifestyle counseling, and further diagnostic workup.
According to the American Heart Association's 2024 Heart Disease and Stroke Statistics, cardiovascular disease remains the leading cause of death in the United States, responsible for roughly 1 in every 5 deaths annually. The Framingham score was designed precisely to identify people at elevated risk beforea first event — while there is still time to intervene.
The Eight Inputs: What Goes Into the Score
Every variable in the Framingham model was selected because it independently predicted coronary events in the original cohort. Here is what each input measures and why it matters:
| Input | What It Measures | Why It Matters |
|---|---|---|
| Age | Years (30–74 in original model) | Coronary risk roughly doubles each decade after 40 |
| Sex | Male or female | Separate point tables; men have higher baseline risk at younger ages |
| Total Cholesterol | mg/dL | Higher total cholesterol increases plaque formation risk |
| HDL Cholesterol | mg/dL | Higher HDL is protective; low HDL is a major independent risk factor |
| Systolic Blood Pressure | mmHg | Elevated SBP strains arterial walls and accelerates atherosclerosis |
| Blood Pressure Treatment | Yes / No | Treated hypertension carries higher residual risk than untreated at the same SBP value |
| Smoking Status | Current smoker vs. non-smoker | Smoking doubles coronary risk; it damages endothelium and promotes clot formation |
| Diabetes Status | Diabetic vs. non-diabetic | Type 2 diabetes is considered a coronary heart disease risk equivalent in many guidelines |
The calculator assigns points to each value, sums the total, and looks it up in a sex-specific table to produce the 10-year risk percentage. Our Framingham Risk Calculator handles this point math automatically.
Risk Categories: What Your Score Means
The three standard risk tiers used in clinical practice are:
| Risk Category | 10-Year CHD Risk | Typical Clinical Response |
|---|---|---|
| Low | Less than 10% | Lifestyle counseling; reassess in 4–6 years |
| Intermediate | 10% to 19% | Discuss statin therapy; consider coronary artery calcium (CAC) scoring |
| High | 20% or more | Statin therapy generally recommended; aggressive lifestyle modification |
A fourth category worth knowing: patients with established cardiovascular disease, diabetes, or LDL above 190 mg/dL are automatically treated as very high risk regardless of their calculated score, per ACC/AHA guidelines.
What the Score Drives Clinically
Statin Threshold: 7.5% and 10%
The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends a clinician–patient discussion about statin therapy when 10-year ASCVD risk is 7.5% or higher. The evidence base strengthens considerably at 10% or above, where statins are broadly recommended in the absence of contraindications.
The Framingham score predicts coronary events specifically, while the newer ACC/AHA Pooled Cohort Equations (PCE) predict broader ASCVD events including stroke. Clinicians often use the Framingham score as a quick screen and the PCE for formal risk stratification. Both tools share most of the same inputs.
Aspirin Discussions
Updated 2022 guidance from the U.S. Preventive Services Task Force (USPSTF) significantly narrowed primary prevention aspirin recommendations. For adults aged 40–59 with a 10-year CVD risk of 10% or more, aspirin may be appropriate after an individualized discussion weighing bleeding risk. The Framingham score helps identify who falls into that conversation.
Lifestyle Interventions and Further Testing
For intermediate-risk patients where the treatment decision is uncertain, clinicians may order a coronary artery calcium (CAC) score— a CT scan that directly measures calcified plaque in the coronary arteries. According to the 2018 ACC/AHA Cholesterol Guidelines, a CAC score above zero in an intermediate-risk patient tips the recommendation toward statin therapy in most cases.
5 Modifiable Risk Factors That Lower Your Framingham Score
Five of the eight Framingham inputs are directly modifiable. Addressing even one or two can meaningfully shift your risk category.
- Quit smoking. Current smoking is among the most heavily weighted risk factors in the Framingham model. CDC data shows that within 1–2 years of quitting, coronary risk drops substantially, and within 5 years it approaches that of a never-smoker for many outcomes.
- Lower total cholesterol and raise HDL. A 10% reduction in total cholesterol is associated with approximately a 20–30% reduction in coronary heart disease risk, based on meta-analyses of statin trials. Aerobic exercise is one of the few lifestyle interventions that reliably raises HDL.
- Control systolic blood pressure. Every 10 mmHg reduction in SBP reduces major cardiovascular events by roughly 20%, according to a 2016 Lancet meta-analysis of 123 randomized trials. Diet (DASH diet, sodium reduction), weight loss, and antihypertensives all help.
- Manage blood sugar / prevent or control diabetes. Type 2 diabetes roughly doubles coronary risk. Intensive glycemic control, weight loss, and physical activity each reduce progression from prediabetes to diabetes and lower associated cardiovascular risk.
- Achieve and maintain a healthy weight. Obesity drives multiple Framingham risk factors simultaneously — it raises blood pressure, worsens lipid profiles, and is the dominant risk factor for type 2 diabetes. Even a 5–10% reduction in body weight produces clinically meaningful improvements across all four variables above.
4 Limitations of the Framingham Risk Score
The Framingham Risk Score is a powerful tool, but it has real constraints worth understanding.
- Derived from a non-diverse population. The original cohort was overwhelmingly White and middle-class, drawn from a single Massachusetts town. Studies have found the FRS overestimates risk in some groups (e.g., Japanese Americans, some European populations) and underestimates it in others (e.g., South Asians, certain Black populations). The ACC/AHA Pooled Cohort Equations were developed partly to address this.
- Ignores family history. A strong first-degree family history of premature coronary disease (father before age 55, mother before age 65) is a recognized risk enhancer in ACC/AHA guidelines but is not part of the Framingham point system.
- Does not include emerging biomarkers. Inflammatory markers like high-sensitivity CRP (hsCRP), lipoprotein(a), or ApoB are not in the model despite evidence linking them to residual cardiovascular risk beyond traditional factors.
- Predicts coronary events, not all ASCVD. The FRS focuses on heart attack and coronary death. It does not predict stroke or peripheral arterial disease, which the ACC/AHA Pooled Cohort Equations do. For comprehensive risk assessment, most guidelines now prefer the broader ASCVD risk estimate.
Framingham vs. ACC/AHA Pooled Cohort Equations
When the ACC and AHA released updated cholesterol guidelines in 2013, they introduced the Pooled Cohort Equations (PCE) as the preferred tool for primary prevention risk stratification. The key differences:
| Feature | Framingham Risk Score | ACC/AHA Pooled Cohort Equations |
|---|---|---|
| Outcomes predicted | Coronary events (MI, coronary death) | ASCVD events (MI, coronary death, stroke) |
| Cohort diversity | Primarily White, single location | Multiple cohorts including Black adults |
| Age range | 30–74 | 40–79 |
| Race-specific equations | No | Yes (White, Black; others use White equation) |
| Guideline preference | Widely used in research | Preferred for ACC/AHA statin decisions |
In practice, both tools are useful. The Framingham score remains a gold standard in research and is the basis for many international cardiovascular risk tools (including the British QRISK and European SCORE systems). For clinical statin prescribing decisions in the US, the PCE is now the primary reference.
Know your 10-year heart disease risk
Use our free Framingham Risk Calculator →Frequently Asked Questions
What is a good Framingham Risk Score?
A Framingham Risk Score below 10% is considered low risk, meaning less than a 1-in-10 chance of a heart attack or coronary death in the next 10 years. Scores of 10–19% are intermediate risk, and 20% or more is high risk. Most clinicians target a score below 7.5% before considering statin therapy.
What inputs does the Framingham Risk Score use?
The Framingham Risk Score uses eight variables: age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, whether blood pressure is being treated, smoking status, and diabetes status. Each factor is weighted by a points system derived from the original Framingham Heart Study cohort data.
Is the Framingham Risk Score still used by doctors?
Yes, though it has largely been supplemented by the ACC/AHA Pooled Cohort Equations introduced in 2013, which extend risk prediction to stroke and are validated in more diverse populations. Many clinicians use both tools together. The Framingham score remains widely referenced in clinical research and patient education.
How can I lower my Framingham Risk Score?
The most impactful modifiable factors are quitting smoking (can cut risk by 30–50% within a year), lowering LDL cholesterol through diet and statins, controlling blood pressure below 130/80 mmHg, managing blood sugar if diabetic, and achieving a healthy weight. Even a 10% reduction in total cholesterol lowers coronary risk by roughly 20%.
At what Framingham score do doctors prescribe statins?
The 2019 ACC/AHA guidelines recommend discussing statin therapy when 10-year atherosclerotic cardiovascular disease (ASCVD) risk reaches 7.5% or higher, with statins strongly recommended at 10% or above. The Framingham score is often used as a screening tool to identify patients who warrant this conversation with their physician.
What are the limitations of the Framingham Risk Score?
The Framingham Risk Score was derived from a predominantly White, middle-class cohort in Massachusetts and may overestimate risk in some populations and underestimate it in others. It does not account for family history, coronary artery calcium score, inflammatory markers like hsCRP, or newer risk enhancers such as chronic kidney disease.